StevensPE, AhmedSB, CarreroJJ, FosterB, FrancisA, HallRK, et al.: KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int105: S117–S314, 202410.1016/j.kint.2023.10.018PubMed
StevensPE, AhmedSB, CarreroJJ, FosterB, FrancisA, HallRK, : KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105: S117–S314, 202410.1016/j.kint.2023.10.018PubMed)| false
JohansenKL, ChertowGM, GilbertsonDT, IshaniA, IsraniA, KuE, et al.: US Renal Data System 2022 annual data report: Epidemiology of kidney disease in the United States. Am J Kidney Dis81: A8–A11, 202310.1053/j.ajkd.2022.12.001PubMed
JohansenKL, ChertowGM, GilbertsonDT, IshaniA, IsraniA, KuE, : US Renal Data System 2022 annual data report: Epidemiology of kidney disease in the United States. Am J Kidney Dis 81: A8–A11, 202310.1053/j.ajkd.2022.12.001PubMed)| false
LiyanageT, ToyamaT, HockhamC, NinomiyaT, PerkovicV, WoodwardM, et al.: Prevalence of chronic kidney disease in Asia: A systematic review and analysis. BMJ Glob Health7: e007525, 202210.1136/bmjgh-2021-007525PubMed
The UK Kidney Association: 25th annual report - data to 31/12/2021. Available at https://ukkidney.org/audit-research/annual-report/25th-annual-report-data-31122021. Accessed June 17, 2024)| false
AdingwupuOM, BarbosaER, PalevskyPM, VassalottiJA, LeveyAS, InkerLA: Cystatin C as a GFR estimation marker in acute and chronic illness: A systematic review. Kidney Med5: 100727, 202310.1016/j.xkme.2023.100727PubMed
AdingwupuOM, BarbosaER, PalevskyPM, VassalottiJA, LeveyAS, InkerLA: Cystatin C as a GFR estimation marker in acute and chronic illness: A systematic review. Kidney Med 5: 100727, 202310.1016/j.xkme.2023.100727PubMed)| false
DelgadoC, BawejaM, CrewsDC, EneanyaND, GadegbekuCA, InkerLA, et al.: A unifying approach for GFR estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am J Kidney Dis79: 268–288.e1, 202210.1053/j.ajkd.2021.08.003PubMed
DelgadoC, BawejaM, CrewsDC, EneanyaND, GadegbekuCA, InkerLA, : A unifying approach for GFR estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am J Kidney Dis 79: 268–288.e1, 202210.1053/j.ajkd.2021.08.003PubMed)| false
Correa-RotterR, WesselingC, JohnsonRJ: CKD of unknown origin in Central America: The case for a Mesoamerican nephropathy. Am J Kidney Dis Off Dis63: 506–520, 201410.1053/j.ajkd.2013.10.062PubMed
Correa-RotterR, WesselingC, JohnsonRJ: CKD of unknown origin in Central America: The case for a Mesoamerican nephropathy. Am J Kidney Dis Off Dis 63: 506–520, 201410.1053/j.ajkd.2013.10.062PubMed)| false
HannanM, AnsariS, MezaN, AndersonAH, SrivastavaA, WaikarS, Chronic Renal Insufficiency Cohort (CRIC) Study Investigators, et al.: Risk factors for CKD progression: Overview of findings from the CRIC study. Clin J Am Soc Nephrol16: 648–659, 202110.2215/CJN.07830520PubMed
Robinson-CohenC, TriozziJL, RowanB, HeJ, ChenHC, ZhengNS, et al.: Genome-wide association study of CKD progression. J Am Soc Nephrol34: 1547–1559, 202310.1681/ASN.0000000000000170PubMed
JagannathanR, RajagopalanK, HoganJ, HartA, NewellKA, PastanSO, et al.: Association between APOL1 genotype and kidney diseases and annual kidney function change: A systematic review and meta-analysis of the prospective studies. Int J Nephrol Renovasc Dis14: 97–104, 202110.2147/IJNRD.S294191PubMed
JagannathanR, RajagopalanK, HoganJ, HartA, NewellKA, PastanSO, : Association between APOL1 genotype and kidney diseases and annual kidney function change: A systematic review and meta-analysis of the prospective studies. Int J Nephrol Renovasc Dis 14: 97–104, 202110.2147/IJNRD.S294191PubMed)| false
EgbunaO, ZimmermanB, ManosG, FortierA, ChirieacMC, DakinLA, et al.: Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. | N Engl J Med388: 969–979, 2023 10.1056/NEJMoa2202396 PubMed
EgbunaO, ZimmermanB, ManosG, FortierA, ChirieacMC, DakinLA, : Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. | N Engl J Med 388: 969–979, 2023 10.1056/NEJMoa2202396 PubMed)| false
MouraFA, BergDD, BellaviaA, DwyerJP, MosenzonO, SciricaBM, et al.: Risk assessment of kidney disease progression and efficacy of SGLT2 inhibition in patients with type 2 diabetes. Diabetes Care46: 1807–1815, 202310.2337/dc23-0492PubMed
MouraFA, BergDD, BellaviaA, DwyerJP, MosenzonO, SciricaBM, : Risk assessment of kidney disease progression and efficacy of SGLT2 inhibition in patients with type 2 diabetes. Diabetes Care 46: 1807–1815, 202310.2337/dc23-0492PubMed)| false
PasternakM, LiuP, QuinnR, ElliottM, HarrisonTG, HemmelgarnB, et al.: Association of albuminuria and regression of chronic kidney disease in adults with newly diagnosed moderate to severe chronic kidney disease. JAMA Netw Open5: e2225821, 202210.1001/jamanetworkopen.2022.25821PubMed
PasternakM, LiuP, QuinnR, ElliottM, HarrisonTG, HemmelgarnB, : Association of albuminuria and regression of chronic kidney disease in adults with newly diagnosed moderate to severe chronic kidney disease. JAMA Netw Open 5: e2225821, 202210.1001/jamanetworkopen.2022.25821PubMed)| false
HwangS, LeeK, ParkJ, KimDH, JeonJ, JangHR, et al.: Prognostic significance of albuminuria in elderly of various ages with diabetes. Sci Rep13: 7079, 202310.1038/s41598-023-32305-0PubMed
HwangS, LeeK, ParkJ, KimDH, JeonJ, JangHR, : Prognostic significance of albuminuria in elderly of various ages with diabetes. Sci Rep 13: 7079, 202310.1038/s41598-023-32305-0PubMed)| false
AscherSB, BerryJD, KatzR, de LemosJA, BansalN, GarimellaPS, et al.: Changes in natriuretic peptide levels and subsequent kidney function decline in SPRINT. Am J Kidney Dis83: 615–623.e1, 202410.1053/j.ajkd.2023.09.018PubMed
AscherSB, BerryJD, KatzR, de LemosJA, BansalN, GarimellaPS, : Changes in natriuretic peptide levels and subsequent kidney function decline in SPRINT. Am J Kidney Dis 83: 615–623.e1, 202410.1053/j.ajkd.2023.09.018PubMed)| false
Kidney Disease: Improving Global Outcomes: Acute Kidney Injury (AKI). Available from https://kdigo.org/guidelines/acute-kidney-injury/. Accessed July 26, 2024)| false
HorneKL, Viramontes-HörnerD, PackingtonR, MonaghanJ, ShawS, AkaniA, et al.: A comprehensive description of kidney disease progression after acute kidney injury from a prospective, parallel-group cohort study. Kidney Int104: 1185–1193, 202310.1016/j.kint.2023.08.005PubMed
HorneKL, Viramontes-HörnerD, PackingtonR, MonaghanJ, ShawS, AkaniA, : A comprehensive description of kidney disease progression after acute kidney injury from a prospective, parallel-group cohort study. Kidney Int 104: 1185–1193, 202310.1016/j.kint.2023.08.005PubMed)| false
JaquesDA, VollenweiderP, BochudM, PonteB: Aging and hypertension in kidney function decline: A 10 year population-based study. Front Cardiovasc Med9: 1035313, 202210.3389/fcvm.2022.1035313PubMed
JaquesDA, VollenweiderP, BochudM, PonteB: Aging and hypertension in kidney function decline: A 10 year population-based study. Front Cardiovasc Med 9: 1035313, 202210.3389/fcvm.2022.1035313PubMed)| false
KattahAG, GarovicVD: Understanding sex differences in progression and prognosis of chronic kidney disease. Ann Transl Med8: 897, 202010.21037/atm.2020.03.62PubMed
KattahAG, GarovicVD: Understanding sex differences in progression and prognosis of chronic kidney disease. Ann Transl Med 8: 897, 202010.21037/atm.2020.03.62PubMed)| false
MayneKJ, SullivanMK, LeesJS: Sex and gender differences in the management of chronic kidney disease and hypertension. J Hum Hypertens37: 649–653, 202310.1038/s41371-023-00843-9PubMed
MayneKJ, SullivanMK, LeesJS: Sex and gender differences in the management of chronic kidney disease and hypertension. J Hum Hypertens 37: 649–653, 202310.1038/s41371-023-00843-9PubMed)| false
MinutoloR, GabbaiFB, ChiodiniP, ProvenzanoM, BorrelliS, GarofaloC, Collaborative Study Group on the Conservative Treatment of CKD of the Italian Society of Nephrology, et al.: Sex differences in the progression of CKD among older patients: Pooled analysis of 4 cohort studies. Am J Kidney Dis Off Dis75: 30–38, 202010.1053/j.ajkd.2019.05.019PubMed
MinutoloR, GabbaiFB, ChiodiniP, ProvenzanoM, BorrelliS, GarofaloC, Collaborative Study Group on the Conservative Treatment of CKD of the Italian Society of Nephrology, : Sex differences in the progression of CKD among older patients: Pooled analysis of 4 cohort studies. Am J Kidney Dis Off Dis 75: 30–38, 202010.1053/j.ajkd.2019.05.019PubMed)| false
GarofaloC, BorrelliS, ProvenzanoM, De StefanoT, VitaC, ChiodiniP, et al.: Dietary salt restriction in chronic kidney disease: A meta-analysis of randomized clinical trials. Nutrients10: 732, 201810.3390/nu10060732PubMed
KangM, KangE, RyuH, HongY, HanSS, ParkSK, et al.: Measured sodium excretion is associated with CKD progression: Results from the KNOW-CKD study. Nephrol Dial Transplant Off Transplant36: 512–519, 202110.1093/ndt/gfaa107PubMed
KovesdyCP, CoreshJ, BallewSH, WoodwardM, LevinA, NaimarkDMJ, CKD Prognosis Consortium, et al.: Past decline versus current eGFR and subsequent ESRD risk. J Am Soc Nephrol27: 2447–2455, 201610.1681/ASN.2015060687PubMed